Overview

A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Gemcitabine
Sunitinib